The ISIS Technology Platform PGT has an exclusive global license for Isis, an innovative, patent-pending technology platform initially developed to produce effective and low cost vaccines against viral, bacterial and parasitic diseases in animals using bacterial vectors. Isis represents a combination of processes, know-how and genetic sequences that utilizes low-cost recombinant technology for the insertion of bacterial, viral or protozoan genes into bacterial vectors that then produce certain desired antigens, the active components of a vaccine. These antigens are essentially the same (or “universal”) across a range of pathogen strains, serovars and even species. Isis has been successful with both live Salmonella and inactivated Bacillus subtilis vectors. Bacillus subtilis has been chosen in part because it has US FDA GRAS (Generally Regarded As Safe) status, and thus should have a low regulatory threshold in the target market countries and be accepted by the public as a safe. While PGT’s vaccines are very low cost to produce, they are also cost effective to distribute and use. They are relatively stable at room temperature and will have advantages in transportation and storage over current vaccines. They can be delivered orally in water or by spray and in flexible dosages while many of the currently available conventional vaccines are injected. The Isis universal vaccine approach, combined with simple delivery characteristics, have major implications for cost savings and acceptability, especially in the developing world which faces problems with current vaccination procedures. The advantages of PGT’s novel vaccine approach will allow us to compete with the lowest cost commercial producers of more conventional vaccines in the market and to achieve greater acceptability by users in addressing unmet needs. All information on this website has been copyrighted by the company Pacific Gene-Tech and this website is purely to promote and not to be beneficial in any manner. This information does not belong to me it belongs to the company of Pacific Gene-Tech. |
